Related by context. All words. (Click for frequent words.) 65 GSK # 61 hematological malignancies 60 AQ4N 60 Panzem R NCD 60 Perifosine 60 alvespimycin 60 Bezielle 60 Phase Ib clinical trials 60 JAK inhibitor 60 HGS ETR1 59 class mGluR5 inhibitor 59 orally administered inhibitor 58 ganetespib 58 forodesine 58 HGS# 58 XL# anticancer compounds 58 Phase Ib 58 XL# XL# XL# XL# 57 HRPC 57 ofatumumab 57 HspE7 57 HCD# [002] 57 PEG SN# 57 OncoVEX GM CSF 57 MAGE A3 ASCI 57 PEG Interferon lambda 57 CA4P 57 PXD# 57 XL# [003] 57 romidepsin 57 phase IIb clinical 57 oral prodrug 57 perifosine 57 investigational humanized monoclonal antibody 56 dacetuzumab 56 CR# vcMMAE 56 obatoclax 56 dose escalation trial 56 Virulizin ® 56 otelixizumab 56 elotuzumab 56 PEG PAL 56 ridaforolimus 56 CORT # 56 PLK1 SNALP 56 refractory multiple myeloma 56 KRN# 56 pomalidomide 55 GRN#L 55 tolerated dose MTD 55 MAXY alpha 55 Aflibercept 55 BiTE antibody 55 INCB# [001] 55 Panzem R 55 OXi# 55 MGCD# [001] 55 rNAPc2 55 MEK inhibitor 55 entinostat 55 Aurora kinase 55 lesinurad 55 adecatumumab 55 investigational compound 55 IMC A# 55 heavily pretreated 55 PNP inhibitor 55 initiate Phase 1b 55 investigational monoclonal antibody 55 novel histone deacetylase 55 HGS ETR2 55 R#/MEM # 55 CEQ# 55 JAK2 inhibitor 55 HER2 positive metastatic breast 55 tanespimycin 55 talactoferrin 55 mertansine 55 ASONEP 55 Phase IIa clinical trials 54 Nanobody 54 seliciclib 54 Phase 1b 54 tamibarotene 54 imetelstat 54 Phase 2a trial 54 Aurora kinase inhibitor 54 confirmatory Phase III 54 CD4 monoclonal antibody 54 MGCD# [002] 54 sorafenib tablets 54 Fibrillex TM 54 thymalfasin 54 histone deacetylase HDAC inhibitor 54 lintuzumab SGN 54 oral ridaforolimus 54 MT# MEDI 54 AP# [003] 54 XL# XL# XL# 54 MAXY G# 54 PDE4 inhibitor 54 glufosfamide 54 dose escalation 54 Asentar 54 TACI Ig 54 nab paclitaxel 54 huC# DM4 54 evaluating Xcytrin 54 JAK inhibitors 54 T DM1 54 deforolimus 54 Phase 1b clinical 54 Phase 2a clinical trials 54 docetaxel Taxotere R 54 Nicole Onetto MD 54 phase IIa clinical 54 evaluating tivozanib 54 eniluracil 54 targeted radiotherapeutic 54 voreloxin 54 Phase #b/#a clinical 54 ATL# [002] 54 celgosivir 53 TOCOSOL Paclitaxel 53 PDX pralatrexate 53 receptor tyrosine kinase inhibitor 53 tesetaxel 53 iSONEP 53 metaglidasen 53 SCH # 53 PSMA ADC 53 REOLYSIN ® 53 carfilzomib 53 pan HDAC inhibitor 53 Phase 1a 53 XL# XL# 53 resistant ovarian cancer 53 palifosfamide 53 Proxinium TM 53 HIV integrase inhibitor 53 radiation sensitizer 53 Azedra 53 CUDC 53 dose limiting toxicities 53 #D#C# 53 Phase Ib study 53 relapsed refractory multiple myeloma 53 GLPG# 53 Annamycin 53 oncology indications 53 TKM ApoB 53 Cloretazine R VNP#M 53 PD LID 53 ocrelizumab 53 non nucleoside HCV 53 multi kinase inhibitor 53 Atiprimod 53 phase Ib 53 systemic RNAi therapeutic 53 Archexin 53 NGX# 53 hypoxia activated prodrug 53 limiting toxicity 53 Allovectin 7 R 53 JAK1 53 ELND# 53 FOLOTYN 53 registrational 53 OMP #R# 53 Phase 2b trial 53 AKT inhibitor 53 FOLOTYN ® 53 dacetuzumab SGN 53 pertuzumab 53 PS# [001] 53 TELCYTA 53 Chemophase 53 APOPTONE 53 humanized monoclonal antibody 53 hematologic malignancies 53 refractory PTCL 53 TELINTRA 53 Phase 1b trial 53 anti leukemic 53 dose escalation study 53 vosaroxin 53 custirsen 53 platinum refractory 53 CYC# 53 bicifadine 53 ENMD # 53 tezampanel 52 CD# monoclonal antibody 52 Azixa 52 mapatumumab 52 PSN# [002] 52 HGS ETR1 mapatumumab 52 carboplatin paclitaxel 52 GAP #B# 52 antitumor activity 52 Romidepsin 52 relapsed multiple myeloma 52 tgAAC# 52 Anturol 52 BZL# 52 GED aPC 52 trastuzumab emtansine T DM1 52 sorafenib Nexavar ® 52 YONDELIS 52 CCR5 mAb 52 dose escalation Phase 52 Aplidin R 52 Sudhir Agrawal D.Phil 52 liposomal formulation 52 histone deacetylase inhibitor 52 Traficet EN 52 Troxatyl 52 IMGN# 52 IAP inhibitors 52 epothilone 52 TRISENOX 52 depsipeptide 52 BCX# 52 Tamibarotene 52 lintuzumab 52 torezolid phosphate 52 CD# antibody [001] 52 visilizumab 52 Phase Ib clinical 52 NP2 Enkephalin 52 ARIKACE ™ 52 HuMax CD4 52 virus HCV protease inhibitor 52 cetrorelix 52 valopicitabine 52 synthetic retinoid 52 Allovectin 7 ® 52 Exelixis XL# 52 AEG# 52 pralatrexate 52 ThermoDox R 52 OvaRex R 52 proteasome inhibitor 52 Apoptone 52 PRT# 52 carboplatin 52 metastatic CRC 52 axitinib 52 mitogen activated ERK kinase 52 refractory chronic lymphocytic 52 RGB # 52 selective kinase inhibitor 52 preclinical 52 ZYBRESTAT fosbretabulin 52 #ME# 52 atacicept 52 Phase #b/#a 52 solid tumors 52 Phase IIa clinical 52 kinase inhibitor 52 Phenoptin 52 CYT# potent vascular disrupting 52 aflibercept VEGF Trap 52 tremelimumab 52 EVIZON TM squalamine lactate 52 Aurexis 52 polymerase inhibitor 52 velafermin 52 immunosuppressive compound 52 RDEA# 52 Imprime PGG 52 cutaneous T cell 52 telaprevir VX 52 aflibercept 52 Maximum Tolerated Dose MTD 52 oral proteasome inhibitor 52 Phase 2b study 52 Aplidin 52 Symadex 52 Allovectin 7 52 Synavive 52 orally bioavailable 52 ApoB SNALP 52 motesanib 52 Phase IIa trials 52 nonclinical studies 52 Carfilzomib 51 blinded randomized placebo controlled 51 Neuradiab 51 BAY #-# 51 Omacetaxine 51 Voreloxin 51 ISTODAX 51 AEZS 51 opioid induced bowel dysfunction 51 pradefovir 51 Laquinimod 51 RiVax ™ 51 bortezomib 51 Phase 2a 51 lumiliximab 51 LY# [003] 51 CD# CEA 51 dasatinib Sprycel ® 51 Vicinium TM 51 indibulin 51 novel anticancer 51 bendamustine 51 PRX# 51 GALNS 51 CORLUX CORT # 51 DB# [003] 51 RG# [001] 51 CCR9 antagonist 51 vidofludimus 51 farletuzumab 51 TRX1 51 lenalidomide Revlimid R 51 RhuDex ® 51 Phase Ib II 51 candidate AQ4N 51 selective androgen receptor modulator 51 IMA# 51 Bortezomib 51 L BLP# 51 leading oral taxane 51 novel topoisomerase 51 RH1 51 ELACYT 51 GRNVAC1 51 Exelixis compounds 51 gemcitabine Gemzar ® 51 TORISEL 51 albinterferon alfa 2b 51 gemcitabine chemotherapy 51 Phase IIb trials 51 CTCE 51 castration resistant prostate cancer 51 AVN# [001] 51 R roscovitine 51 bortezomib Velcade R 51 Insegia 51 Solazed 51 Zevalin R Ibritumomab 51 IgG1 monoclonal antibody 51 DermaVir Patch 51 AzaSite Plus 51 Amigal 51 belinostat 51 alkylating agent 51 VEGFR2 inhibitor 51 pegylated liposomal doxorubicin 51 oral deforolimus 51 oral antiviral 51 tivozanib 51 Exherin TM 51 novel VDA molecule 51 Phase #/#a trial 51 MEK inhibitor RDEA# 51 CDK cyclin dependent 51 Bicifadine 51 ENMD 51 TKM PLK1 51 Phase IIa trial 51 Blinatumomab 51 ARRY 51 Elotuzumab 51 CCX# 51 combinability 51 ThermoDox ® clinical 51 phase IIb 51 compound INCB# 51 EGFR HER2 50 interferon gamma 1b 50 confirmatory Phase 3 50 NKTR 50 evaluating pirfenidone 50 ONX 50 HuLuc# 50 dextromethorphan quinidine 50 Viramidine 50 Seliciclib 50 Phase 2b clinical 50 alpha folate receptor 50 CTAP# Capsules 50 Solazed TM 50 IRX 2 50 Tyrima 50 galiximab 50 ponatinib 50 advanced NSCLC 50 Pralatrexate 50 ANYARA 50 Ceflatonin 50 ThermoDox ® 50 NEUVENGE 50 XmAb# 50 IAP inhibitor 50 Sym# 50 OMP #M# 50 ularitide 50 FOLFOX6 50 IIa trial 50 investigational oral 50 vascular disrupting agent 50 metastatic hormone refractory 50 AAG geldanamycin analog 50 apaziquone 50 2 methoxyestradiol 50 cilengitide 50 Ocrelizumab 50 TBC# 50 samalizumab 50 PF # [001] 50 oral JAK#/JAK# inhibitor 50 AZD# 50 Nexavar ® 50 Preclinical studies 50 veltuzumab 50 R sorafenib tablets 50 MEK inhibitors 50 sapacitabine 50 Glufosfamide 50 angiogenesis inhibitor 50 HDAC Inhibitor 50 RITUXAN 50 ixabepilone 50 IMC #B 50 Menerba 50 Trofex 50 CRx 50 KNS # 50 Talabostat 50 Phase III clinical 50 ongoing Phase 1b 50 Phase IIb 50 PI3K/Akt pathway inhibitor 50 tesmilifene 50 docetaxel 50 PRTX 50 volociximab 50 immunomodulatory therapy 50 hematological cancers 50 MAP# 50 teduglutide 50 TransVax ™ 50 trastuzumab Herceptin R 50 Panzem NCD 50 AZX# 50 baminercept 50 evaluating satraplatin 50 vandetanib 50 R#/MEM 50 forodesine HCl 50 MKC# PP 50 HCV protease inhibitor 50 multicenter Phase 50 Darinaparsin 50 registrational trial 50 eculizumab 50 dirucotide 50 HCV protease 50 HuMax EGFr 50 NSCLC 50 humanized anti 50 elagolix 50 LEP ETU 50 BRIM2 50 androgen independent 50 GSK# [001] 50 eltrombopag 50 Factor VIIa 50 elacytarabine 50 Cloretazine 50 indolent NHL 50 phase 2a 50 neratinib 50 Nuvion 50 ARRY # 50 Phase 2a clinical 50 EOquin TM 50 cell lymphoma CTCL 50 PRX # 50 AeroLEF TM 50 drug conjugate 50 SARMs 50 Hsp# inhibition 50 Alpharadin 50 ulimorelin 50 xenograft models 50 forodesine hydrochloride 50 Tarceva TM 50 adecatumumab MT# 50 Abiraterone acetate 50 docetaxel chemotherapy 50 Entereg R 50 Protexia R 50 ATL# [001] 50 Allovectin 7 r 50 advanced carcinoid 50 blinatumomab 50 #I TM# 50 ACAPODENE TM 50 oral isoform selective HDAC 50 Tarvacin TM 50 L Annamycin 50 Zerenex 50 dimebon 50 lomitapide 50 epratuzumab 50 Virulizin R 50 FOLFOX6 chemotherapy regimen 50 Æterna Zentaris 50 cancer neuroendocrine tumor 50 Cloretazine ® 50 MNTX 50 sunitinib malate 50 CYT# 50 ALKS 49 ASA# 49 AEGR 49 EOquin 49 autoimmune indications 49 APD# 49 CTA# Injection 49 dose cohorts 49 Triapine R 49 trodusquemine 49 metastatic RCC 49 pivotal Phase III 49 Kevetrin 49 dose cohort 49 multicenter Phase II 49 tubulin inhibitor 49 gemcitabine 49 posaconazole 49 APF# 49 phase IIb study 49 MDV# 49 EndoTAG TM -1 49 Actilon 49 TLK# 49 Phase 2b 49 preclinical studies 49 TNFerade 49 THR beta agonist 49 enzastaurin 49 IMiDs 49 ALN TTR# 49 COU AA 49 Phase Ia 49 rindopepimut 49 Phase IIb clinical trials 49 DAVANAT R 49 Budesonide MMX 49 IDX# 49 OvaRex ® MAb 49 talabostat 49 cannabinor 49 investigational drug 49 Ixempra 49 TAFA# 49 ZACTIMA 49 oral picoplatin 49 glioblastoma multiforme GBM 49 recurrent metastatic ovarian cancer 49 Genasense ® 49 Intravenous CP 49 paclitaxel Taxol ® 49 Serdaxin 49 Protexia ® 49 CD3 monoclonal antibody 49 targeting CD# 49 CIMZIA TM 49 Thiovir 49 GV# [001] 49 Amrubicin 49 immunomodulator 49 mGluR5 negative 49 refractory AML 49 Atu# 49 GATTEX ® 49 UVIDEM 49 pegloticase 49 DAVANAT 49 ONTAK 49 refractory CLL 49 CBLC# 49 REOLYSIN 49 favorable pharmacokinetic profile 49 Sulonex TM 49 TG# [003] 49 Amplimexon 49 anticancer compound 49 velafermin belinostat 49 monotherapy 49 TYKERB 49 tezampanel NGX# 49 JAK3 49 metastatic HRPC 49 olaparib 49 picoplatin 49 Phase 2b clinical trials 49 Phase IIb clinical 49 temsirolimus 49 pharmacodynamic 49 TRIOLEX 49 LymphoStat B 49 Debio 49 SUCCEED trial 49 methylnaltrexone 49 Panzem 49 GFT# 49 Stedivaze 49 Ceplene/IL-2 49 Syncria 49 GMX# 49 MOZOBIL 49 BLA filing 49 INCB# [002] 49 huN# DM1 49 TRAIL receptor antibodies 49 BR.# 49 Protectan CBLB# 49 GVAX ® 49 ISIS # 49 Xeloda ® 49 Anticalin R 49 SCCHN 49 Dapagliflozin 49 GLP toxicology studies 49 Daclizumab 49 ZK EPO 49 ALN TTR 49 multiple myeloma MM 49 recurrent glioblastoma 49 LEUKINE 49 Panitumumab 49 daclizumab 49 metastatic renal cell carcinoma 49 dependent kinase inhibitor 49 MGd 48 Androxal TM 48 HQK 48 BNC# 48 ALK inhibitor 48 apremilast 48 TG# [001] 48 LE DT 48 Phase III 48 viral kinetic 48 Epratuzumab 48 ICA # 48 preclinical efficacy 48 multiple ascending dose 48 Pimavanserin 48 panitumumab Vectibix 48 cancer immunotherapies 48 refractory gout 48 FOLFIRI chemotherapy 48 SparVax TM 48 unique alkylating agent 48 myeloproliferative disorders 48 PROMACTA 48 erlotinib Tarceva ® 48 optimal dosing 48 isoform selective 48 Octreotide 48 sodium thiosulfate STS 48 maximally tolerated dose 48 BEMA Buprenorphine 48 antibody MAb 48 EGFR expressing mCRC 48 phase IIa 48 danoprevir 48 cetuximab Erbitux R 48 Elagolix 48 phase IIb trial 48 NVA# 48 Vilazodone 48 novel therapeutic antibodies 48 PCK# 48 telomerase therapeutic 48 Tanespimycin 48 placebo controlled Phase 48 Talactoferrin 48 anticancer therapies 48 Neulasta ® 48 Azedra TM 48 intravesical infusion therapy 48 decitabine 48 PREOS 48 Topical Interferon Alpha 2b 48 linaclotide 48 anticancer agent 48 agonistic human 48 rALLy clinical trial 48 SNT MC# 48 Phase II 48 dosing cohort 48 Phase III confirmatory 48 pivotal Phase 48 sapacitabine CYC# 48 docetaxel Taxotere 48 PKC# 48 NXL# 48 docetaxel Taxotere ® 48 MBP# [001] 48 Pazopanib 48 limiting toxicity DLT 48 Poly ICLC 48 mTOR inhibitor 48 sodium glucose cotransporter 48 taxane 48 cleavable linker 48 darinaparsin 48 brentuximab vedotin 48 SAR# [004] 48 Dacogen injection 48 Gemzar ® 48 elesclomol 48 Zemiva TM Trofex TM 48 ZYBRESTAT 48 safety tolerability pharmacokinetics 48 leukemia AML 48 Chrysalin 48 Ostarine 48 FOLFIRI 48 amrubicin 48 non nucleoside polymerase 48 Vitaxin 48 brivaracetam 48 DOS# 48 Guanilib 48 lymphoma CTCL 48 personalized immunotherapy 48 AGGRASTAT ® 48 OMAPRO 48 bevacizumab Avastin ® 48 investigational therapies 48 telomerase inhibitor drug 48 FLT3 48 Apaziquone 48 PANVAC VF 48 Ofatumumab 48 Viprinex 48 IoGen 48 ARQ 48 cisplatin gemcitabine 48 omecamtiv mecarbil 48 Civacir 48 evaluating picoplatin 48 CoFactor 48 TASKi3 48 randomized Phase 48 Xanafide 48 assessing T DM1 48 LUX Lung 48 Vidofludimus 48 regorafenib 48 CCR2 48 Phase 1a clinical 47 Golimumab 47 teplizumab 47 VAPRISOL 47 TREANDA 47 Phase IIIb clinical 47 LHRH antagonist 47 ACTEMRA TM 47 GRN# 47 Advaxis Phase 47 PNT# 47 favorable tolerability 47 bazedoxifene 47 anti EGFR antibody 47 vorinostat 47 brentuximab vedotin SGN 47 Hsp# Inhibitor 47 IND enabling 47 Xcytrin 47 hepatocellular carcinoma 47 anti CD3 monoclonal 47 TOLAMBA 47 alvimopan 47 ruxolitinib 47 nucleoside tide 47 XL# SAR# 47 Zybrestat 47 TMC# [002] 47 Urocidin TM 47 Ixabepilone 47 seliciclib CYC# 47 Immunotherapeutic 47 PF # [002] 47 metastatic colorectal cancer 47 BioNumerik 47 ZFP Therapeutics 47 Sapacitabine 47 CCX# B 47 Tovaxin 47 ® bortezomib 47 Hsp# inhibitor 47 afatinib 47 Hsp# inhibitors 47 QLT# 47 pralatrexate injection folate analogue 47 Lovaxin C 47 product platforms AZX# 47 pharmacodynamic markers 47 trastuzumab DM1 T DM1 47 novel peptide 47 Initiate Phase 47 SinuNase 47 MyVax R 47 pharmacodynamic PD 47 mTOR inhibitors 47 refractory Hodgkin lymphoma 47 trastuzumab DM1 47 imatinib Gleevec ® 47 ALD# 47 teriflunomide 47 GW# [003] 47 vemurafenib 47 CLORETAZINE TM VNP#M 47 fosbretabulin 47 LymphoStat B belimumab 47 imetelstat GRN#L 47 LymphoStat B TM 47 LibiGel Phase III 47 Randomized Phase 47 DPX Survivac 47 alfa 2a 47 Trofex TM 47 INCB# [003] 47 Cloretazine R 47 JAK2 47 RNAi therapeutic 47 Vandetanib 47 CCR5 antagonist 47 INT# [002] 47 Reolysin 47 omega interferon 47 anticancer agents 47 Phase IIb trial 47 ZADAXIN 47 ORE# 47 CK # 47 Epothilones 47 NEUMUNE 47 Surfaxin LS 47 bavituximab 47 modified glutathione analog 47 Revlimid lenalidomide 47 Cethrin 47 GATTEX TM 47 MEND CABG II 47 Triolex 47 Pemetrexed 47 Tectin TM 47 PrevOnco 47 refractory NSCLC 47 mocetinostat MGCD# 47 initiated Phase 1b 47 BiTE 47 ProLindac 47 ALN VSP 47 Targretin 47 relapsed refractory 47 MEK Inhibitor 47 metastatic castration resistant 47 cMET 47 EGS# 47 vilazodone 47 PEGPH# 47 protein kinase inhibitor 47 eritoran 47 tiapamil 47 vernakalant oral 47 satraplatin 47 mitomycin 47 subcutaneous formulation 47 PLX# 47 oral Azacitidine 47 lorvotuzumab mertansine 47 Virulizin 46 recurrent NSCLC 46 laquinimod 46 CINTREDEKIN BESUDOTOX 46 VEGF Trap 46 preclinical models 46 Kosan dependence 46 TLR8 agonist 46 relapsed SCLC 46 Pivotal Phase 46 prostate cancer AIPC 46 LBH# 46 PAC G#P 46 alpha#beta# integrin 46 Phase III Pivotal 46 humanized antibody 46 maribavir 46 gefitinib 46 pharmacokinetic PK study 46 ON #.Na 46 taribavirin 46 low dose cytarabine 46 Anticalin 46 Poly ICR 46 Marqibo 46 cediranib 46 Fx #A 46 BRAF inhibitor 46 oral taxane 46 AACR NCI EORTC 46 R bortezomib 46 GVAX immunotherapy 46 candidates bavituximab 46 Aptivus ® 46 initiated Phase Ib 46 capecitabine Xeloda R 46 ostarine 46 Plicera 46 rFIXFc 46 PrevOnco ™ 46 AzaSite Xtra 46 Dose Limiting Toxicity DLT 46 sorafenib Nexavar 46 Lenocta TM 46 PEP# [003] 46 Myocet 46 Azedra ™ 46 BCIRG 46 ITMN 46 hormone LHRH antagonist 46 clofarabine 46 fallopian tube cancers 46 Onco TCS 46 Ceflatonin R 46 bafetinib 46 paclitaxel carboplatin 46 tolerability profile 46 gallium containing 46 muraglitazar 46 dose escalation clinical 46 Belinostat 46 abiraterone acetate 46 renin inhibitor 46 Proellex TM 46 ISTODAX ® 46 Taxotere ® 46 Revimmune 46 BrachySil TM 46 ongoing Phase IIIb 46 StemEx 46 commercialize deforolimus 46 Fodosine 46 Onalta 46 metastatic GIST 46 mCRC 46 metastatic melanoma 46 candidate CRLX# 46 FavId 46 darapladib 46 Zemiva TM 46 refractory cutaneous T 46 Lenocta 46 temozolomide 46 Darusentan 46 adjuvant GIST 46 plus gemcitabine 46 Virosome Biologicals 46 Alnylam #x# 46 pediatric acute lymphoblastic 46 TASKi2 46 systemically administered 46 subcutaneous SC 46 ONCONASE R 46 Metastatic Melanoma 46 SRT# [003] 46 randomized discontinuation trial 46 alagebrium 46 Intarcia 46 Tarvacin 46 TRO# 46 Phase IIa 46 Zolinza 46 ALN PCS 46 PRECISE Trial 46 peginesatide 46 BRIM3 46 Tumour Vascular Disrupting Agent 46 CBLB# 46 UPLYSO 46 Exherin 46 antisense drug 46 pazopanib 46 Canvaxin 46 RSD# 46 ONCONASE